RVL Pharmaceuticals plc's latest marketcap:
As of 07/05/2025, RVL Pharmaceuticals plc's market capitalization has reached $111. According to our data, RVL Pharmaceuticals plc is the 49557th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 111 |
| Revenue (ttm) | 36.92 M |
| Net Income (ttm) | -68,266,000 |
| Shares Out | 111.41 M |
| EPS (ttm) | -0.7 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/14/2025 |
RVL Pharmaceuticals plc's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $111 | 0% | 49557 |
| 12/31/2024 | $111 | -99.97% | 48575 |
| 12/29/2023 | $334,218 | -99.7% | 46899 |
| 12/30/2022 | $111.05 M | 23.46% | 45155 |
| 12/31/2021 | $89.95 M | -65.11% | 43117 |
| 12/31/2020 | $257.85 M | -28.96% | 39865 |
| 12/31/2019 | $362.96 M | -10.82% | 37140 |
| 12/31/2018 | $407.02 M | 35729 |
Company Profile
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutical products. The company focuses on addressing unmet medical needs in underserved patient populations, particularly in the ocular and medical aesthetics therapeutic areas.
Key Focus Areas
- Ocular Therapeutics: Specializes in treatments for eye-related conditions.
- Medical Aesthetics: Offers solutions for aesthetic and cosmetic medical needs.
Flagship Product
The company commercializes Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution designed to treat acquired blepharoptosis (low-lying eyelid) in adults.
Corporate Background
Formerly known as Osmotica Pharmaceuticals plc, the company rebranded to RVL Pharmaceuticals plc in January 2022.
Headquarters
RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey, with operations extending to the United States, Argentina, and Hungary.
Frequently Asked Questions
-
What is RVL Pharmaceuticals plc's (OTC-RVLPQ) current market cap?As of 07/05/2025, RVL Pharmaceuticals plc (including the parent company, if applicable) has an estimated market capitalization of $111 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does RVL Pharmaceuticals plc (OTC-RVLPQ) rank globally by market cap?RVL Pharmaceuticals plc global market capitalization ranking is approximately 49557 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.